IMU (ASX) Ann: Imugene PD1-Vaxx patent extended to 2040

Originally posted by Jase99: ↑

I don't usually lookup patents, but I was really intrigued as to how they were able to extend it and I think I've found the reason; which may also explain why there is yet to be a deal for HER-Vaxx and one of the reasons for the HER-Vaxx combo trial with Pembrolizumab.

Here's a link to a copy of the patent: WO2018183488 HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF (wipo.int)

Whilst I haven't checked this against the original patent, I found these parts extremely interesting:

15. The pharmaceutical composition of claim 14, further comprising one or more HER-2 B cell epitopes.
16. The pharmaceutical composition of claim 15, wherein the HER-2 B cell epitopes comprises one or more of the sequences as set forth in SEQ ID NO: 27 or 29.
17. The pharmaceutical composition of claim IS, wherein the HER-2 B cell epitopes comprises one or more synthetic HER-2 B cell epitopes as set forth in SEQ ID NO: 28 or 30.
23. The method of any of claims 20-22, wherein the cancer is selected from the group of cancers consisting of lymphoma, B cell lymphoma, T cell lymphoma, mycosis fungoides, Hodgkin's Disease, myeloid leukemia, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, squamous cell carcinoma of head and neck, lung cancer, small cell lung carcinoma, non-small cell lung carcinoma, neuroblastoma, glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, squamous cell carcinomas of the mouth, throat, larynx, and lung, colon cancer, cervical cancer, cervical carcinoma, breast cancer, epithelial cancer, renal cancer, genitourinary cancer, pulmonary cancer, esophageal carcinoma, head and neck carcinoma, large bowel cancer, hematopoietic cancer; testicular cancer; prostatic cancer, or pancreatic cancer.
24. The method of claim 23, wherein the cancer is breast cancer.
25. The method of claim 24, wherein the method further comprises administering to the subject one or more one or more HER-2 B cell epitopes.
26. The method of claim 25, wherein the HER-2 B cell epitopes comprises one or more of the sequences as set forth in SEQ ID NO: 27 or 29.
27. The method of claim 25, wherein the HER-2 B cell epitopes comprises one or more synthetic HER-2 B cell epitopes as set forth in SEQ ID NO: 28 or 30.
28. The method of claim 25, wherein the HER-2 B cell epitopes are administered in the same composition with the PD-1 epitopes.

Have a look at all the cancers they are expecting to target with PD1-Vaxx.
It appears IMU is planning to do a PD1-Vaxx - HER-Vaxx combination and may well be the reason for holding off on licencing HER-Vaxx as a standalone product.

I also found this part very interesting:

20. A method of treating a cancer, Alzheimer's disease, or autoimmune disease in a subject comprising administering to the subject any of the peptides or compositions of any of claims 1- 19.
21. A method of treating a cancer, Alzheimer' s disease, or an autoimmune disease in a subject comprising administering to a subject a PD-1 chimeric peptide wherein the chimeric peptide comprises one or more PD-1 B cell epitopes, a T helper (Th) epitope, and a linker joining the PD-1 B cell epitope to the Th epitope, wherein the one or more PD-1 B cell epitopes consist of a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5.
22. A method of treating a cancer, Alzheimer's disease, or autoimmune disease in a subject comprising administering to a subject a PD-1 synthetic peptide wherein the PD-1 synthetic peptide comprises one or more of the sequences as set forth in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.
29. The method of any of claims 20-22, wherein the autoimmune disease is selected from the group consisting of Psoriasis, Alopecia Areata, Primary biliary cirrhosis, Autoimmune polyendocrine syndrome, Diabetes mellitus type 1, autoimmune thyroiditis, Systemic Lupus Erythematosus, Multiple sclerosis, Guillain-Barre syndrome, Grave's disease, Sjogren's syndrome, ulcerative colitis, Autoimmune hemolytic anemia, Pernicious anemia, Psoriatic arthritis, rheumatoid arthritis, relapsing polychondritis, myasthenia gravis, Acute disseminated encephalomyelitis, and Granulomatosis with polyangiitis.

I wasn't aware PD1 targeting drugs could be used for other diseases, but it seems there must research to suggest it may be helpful, otherwise why bother including it in the patent?

Expand

That is actually pretty interesting as like yourself I thought it was just cancer it was looking to treat.
it may well be nothing and has just grouped them together for whatever reason.
There's me thinking "meh, just extending a patent by a couple of years. No biggy really"

No.	Vol.	Price($)
32	3441484	5.4¢

No.

Vol.

Price($)

3441484

5.4¢

Price($)	Vol.	No.
5.5¢	574188	6

Price($)

Vol.

No.

5.5¢

574188

No.	Vol.	Price($)
24	2626814	0.054
21	3124322	0.053
28	4941821	0.052
31	3703294	0.051
70	6394327	0.050

No.

Vol.

Price($)

2626814

0.054

3124322

0.053

4941821

0.052

3703294

0.051

6394327

0.050

Price($)	Vol.	No.
0.055	401800	3
0.056	100000	1
0.057	444535	7
0.058	400000	2
0.059	350000	3

Price($)

Vol.

No.

0.055

401800

0.056

100000

0.057

444535

0.058

400000

0.059

350000

(20min delay)
Last 5.4¢		Change -0.002(3.57%)		Mkt cap ! $401.6M

Open	High	Low	Value	Volume
5.6¢	5.7¢	5.4¢	$1.182M	21.47M

That is actually pretty interesting as like yourself I thought...

CBA breaks trading record on strong day for Aussie financials

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Shekel Brainweigh investor presentation webinar – the future of retail automation

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

As Nvidia cools, we're looking to Aussie AI

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

That is actually pretty interesting as like yourself I thought...

Top Stories

CBA breaks trading record on strong day for Aussie financials

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Shekel Brainweigh investor presentation webinar – the future of retail automation

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

As Nvidia cools, we're looking to Aussie AI

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News